title: Evaluation of antitumor activity of a TGF-beta receptor I inhibitor (SD-208) on human colon adenocarcinoma.
abstract: BACKGROUND
  Transforming growth factor-β (TGF-β) pathway is involved in primary tumor progression and in promoting metastasis in a considerable proportion of human cancers such as colorectal cancer (CRC). Therefore, blockage of TGF-β pathway signaling via an inhibitor could be a valuable tool in CRC treatment.
  
  
  METHODS
  To evaluate the efficacy of systemic targeting of the TGF-β pathway for therapeutic effects on CRC, we investigated the effects of a TGβRI (TGF-β receptor 1) or TβRI kinase inhibitor, SD-208, on SW-48, colon adenocarcinoma cells. In this work, in vitro cell proliferation was studied by methyl thiazolyl tetrazolium (MTT) and bromo-2'-deoxyuridine (BrdU) assays. Also, the histopathological and immunohistochemical evaluations were conducted by hematoxylin and eosin, and Ki-67 and CD34 markers were stained, respectively.
  
  
  RESULTS
  Our results showed no significant reduction in cell proliferation and vessel formation (170 ± 70 and 165 ± 70, P > 0.05) in treated SW-48 cells with SD-208 compared to controls.
  
  
  CONCLUSIONS
  Our data suggested that SD-208 could not significantly reduce tumor growth and angiogenesis in human colorectal cancer model at least using SW-48 cells.
authors.forename: Abolfazl
authors.initials: A
authors.lastname: Akbari
authors.forename: Saeid
authors.initials: S
authors.lastname: Amanpour
authors.forename: Samad
authors.initials: S
authors.lastname: Muhammadnejad
authors.forename: Mohammad Hossein
authors.initials: MH
authors.lastname: Ghahremani
authors.forename: Seyed Hamidollah
authors.initials: SH
authors.lastname: Ghaffari
authors.forename: Ahmad Reza
authors.initials: AR
authors.lastname: Dehpour
authors.forename: Gholam Reza
authors.initials: GR
authors.lastname: Mobini
authors.forename: Fatemeh
authors.initials: F
authors.lastname: Shidfar
authors.forename: Mahdi
authors.initials: M
authors.lastname: Abastabar
authors.forename: Ahad
authors.initials: A
authors.lastname: Khoshzaban
authors.forename: Ebrahim
authors.initials: E
authors.lastname: Faghihloo
authors.forename: Abbas
authors.initials: A
authors.lastname: Karimi
authors.affiliation: Stem Cells Preparation Uinte, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran. mheidari@sina.tums.ac.ir.
authors.forename: Mansour
authors.initials: M
authors.lastname: Heidari
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D051379:Mice; D008810:Mice, Inbred C57BL; D009389:Neovascularization, Pathologic / Q000378:metabolism; D011621:Pteridines / Q000494:pharmacology*; D016212:Transforming Growth Factor beta / Q000037:antagonists & inhibitors / Q000378:metabolism*; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; D011621:Pteridines; C511004:SD-208; D016212:Transforming Growth Factor beta